Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27038832 | 0.84 | CYP1A2 (0.47) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 | |
| SCHEMBL20472810 | 0.83 | USP2 (0.47) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 | |
| SCHEMBL18390599 | 0.83 | CYP1A2 (0.54) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 | |
| SCHEMBL30557323 | 0.81 | — | — | |
| SCHEMBL24629668 | 0.81 | CYP3A4 (0.42) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 | |
| SCHEMBL16600244 | 0.81 | CYP3A4 (0.42) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 | |
| SCHEMBL27007062 | 0.81 | USP2 (0.54) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 | |
| SCHEMBL4064514 | 0.79 | CYP2D6 (0.40) | CYP3A4CYP2C19CYP2D6USP2CYP1A2 | |
| SCHEMBL18390602 | 0.78 | CYP3A4 (0.40) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 | |
| SCHEMBL18389871 | 0.78 | CYP3A4 (0.40) | CYP3A4CYP2C19CYP2D6USP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-18 | — | — | US | disclosed |
| EP-2520568-B1 | Spirocyclic nitriles as inhibitors of protease | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| EP-2520568-A1 | Spirocyclic nitriles as inhibitors of protease | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| EP-2032535-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | CYP3A4 3647/4885CYP2C19 4099/4885CYP2D6 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.